Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia by Yee Sook Wah, Mefford Joel A, Singh Natasha, Percival Mary-Elizabeth, Stecula Adrian, Yang Kuo, Witte John S, Takahashi Atsushi, Kubo Michiaki, Matsuda Koichi, Giacomini Kathleen M, Andreadis Charalambos in Journal of human genetics (2013).

[PMID: 23677058] PubMed


Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with a 5-year disease-free survival (DFS) ranging from under 10% to over 70% for distinct groups of patients. At our institution, cytarabine, etoposide and busulfan are used in first or second remission patients treated with a two-step approach to autologous stem cell transplantation (ASCT). In this study, we tested the hypothesis that polymorphisms in the pharmacokinetic and pharmacodynamic pathway genes of these drugs are associated with DFS in AML patients. A total of 1659 variants in 42 genes were analyzed for their association with DFS using a Cox-proportional hazards model. One hundred and fifty-four genetically European patients were used for the primary analysis. An intronic single nucleotide polymorphism (SNP) in ABCC3 (rs4148405) was associated with a significantly shorter DFS (hazard ratios (HR)=3.2, P=5.6 × 10(-6)) in our primary cohort. In addition, a SNP in the GSTM1-GSTM5 locus, rs3754446, was significantly associated with a shorter DFS in all patients (HR=1.8, P=0.001 for 154 European ancestry; HR=1.7, P=0.028 for 125 non-European patients). Thus, for the first time, genetic variants in drug pathway genes are shown to be associated with DFS in AML patients treated with chemotherapy-based autologous ASCT.Journal of Human Genetics advance online publication, 16 May 2013; doi:10.1038/jhg.2013.38.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

No dosing information annotated.